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Background: Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis (WG), belongs
to the group of ANCA-associated necrotizing vasculitides. This study describes the clinical picture of the disease in a
large cohort of GPA paediatric patients.
Children with age at diagnosis ≤ 18 years, fulfilling the EULAR/PRINTO/PRES GPA/WG classification criteria were
extracted from the PRINTO vasculitis database. The clinical signs/symptoms and laboratory features were analysed
before or at the time of diagnosis and at least 3 months thereafter and compared with other paediatric and adult
case series (>50 patients) derived from the literature.
Findings: The 56 children with GPA/WG were predominantly females (68%) and Caucasians (82%) with a median
age at disease onset of 11.7 years, and a median delay in diagnosis of 4.2 months. The most frequent organ
systems involved before/at the time of diagnosis were ears, nose, throat (91%), constitutional (malaise, fever, weight
loss) (89%), respiratory (79%), mucosa and skin (64%), musculoskeletal (59%), and eye (35%), 67% were ANCA-PR3
positive, while haematuria/proteinuria was present in > 50% of the children. In adult series, the frequency of female
involvement ranged from 29% to 50% with lower frequencies of constitutional (fever, weight loss), ears, nose, throat
(oral/nasal ulceration, otitis/aural discharge), respiratory (tracheal/endobronchial stenosis/obstruction), laboratory
involvement and higher frequency of conductive hearing loss than in this paediatric series.
Conclusions: Paediatric patients compared to adults with GPA/WG have similar pattern of clinical manifestations
but different frequencies of organ involvement.
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Comparison with literatureBackground
Granulomatosis with polyangiitis (GPA), previously known
as Wegener’s granulomatosis (WG), [1] is a necrotizing vas-
culitis affecting predominantly small vessels. This disease is
typically associated with granulomatous inflammation,
pauci-immune necrotizing glomerulonephritis, involvement* Correspondence: nicolaruperto@ospedale-gaslini.ge.it
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reproduction in any medium, provided the orof upper and lower respiratory tract, and with presence of
anti-neutrophil cytoplasmic antibodies (ANCA).
The estimated annual incidence of the disease in adults is
1:100,000, and 90% of the patients are Caucasians [2]. In chil-
dren, the estimated incidence is approximately 0.1:100,000
[3]. If untreated, mortality, within one year from diagnosis is
90%. Treatment usually consists of combination of cortico-
steroids and cyclophosphamide, and more recently rituximab
to induce remission, followed by a maintenance phase with
lower doses of corticosteroids combined with azathioprine or
other disease modifying agents for several years. Despitetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Bohm et al. Pediatric Rheumatology 2014, 12:18 Page 2 of 5
http://www.ped-rheum.com/content/12/1/18treatment relapses are common and therapy related compli-
cations of significant concern [4-9].
The clinical and laboratory picture of GPA/WG was de-
scribed in several large cohorts of predominantly adult pa-
tients [10-12] but there is paucity of paediatric data due to
the rare occurrence of the disease in childhood [6,13,14].
Recently, new criteria for childhood GPA/WG have been
established and validated by the European League Against
Rheumatism/Paediatric Rheumatology International Trials
Organisation/Paediatric Rheumatology European Society
(EULAR/PRINTO/PRES) [15-17].
The aim of this project was to describe the clinical and
laboratory features at presentation of childhood GPA/WG
in a large international cohort of paediatric patients col-
lected by PRINTO, and compare this series with other
paediatric series and with adult patients with WG/GPA
derived from the literature.
Patients and methods
The PRINTO database contains data on 1398 patients with
childhood vasculitides, with age at diagnosis ≤ 18 years, vas-
culitis diagnosis after year 2000, as previously described
[16,17]. The database includes demographic data, clinical
diagnosis ascertained by the treating physician and a com-
prehensive list of 70 signs/symptoms (predominantly cat-
egorical variables) in 12 broad organ-system categories,
laboratory parameters, physician global assessment of dis-
ease activity on a 10 cm visual analogue scale (VAS), biopsy
findings and imaging reports. Data have been collected
both retrospectively and prospectively, before or at the time
of diagnosis and at least 3 months later via standardized
web-based case report forms.
For the purposes of this analysis, we extracted all patients
fulfilling the c-GPA/WG EULAR/PRINTO/PRES classifica-
tion criteria [15-17]. Patients with co-morbidities were ex-
cluded from the study. In brief, a patient is classified as
childhood GPA/WG if at least three of the six following cri-
teria are present: 1) histopathology (granulomatous inflam-
mation); 2) upper airway involvement (nasal discharge or
epistaxis/crusts/granulomata, nasal septum perforation or
saddle nose deformity, sinus inflammation); 3) laryngo-
tracheo-bronchial involvement; 4) pulmonary involvement by
chest X-ray or CT; 5) ANCA positivity; 6) renal involvement.
The study was approved by the ethics committee of the
Gaslini Hospital (Genoa, Italy) and by the ethics commit-
tees of all remaining participating centres and informed
consent was obtained from parent(s) as required by the
national law in each participating country.
Comparison with literature data (children and adults)
A PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) search
was used to retrieve studies, which included patients with
GPA/WG (both children and adults), and included both
prospective and retrospective cases describing the clinicalpicture of at least 50 patients. Search terms were “(((Gran-
ulomatosis AND (Wegener OR Wegener’s OR polyangii-
tis)) OR (necrotizing AND vasculitis))) AND (group OR
cohort OR patients) AND (prospective OR prospectively
OR retrospective OR retrospectively) AND demographic
AND age AND clinical AND study” in English.
Statistical analysis
The quantitative demographic, clinical and laboratory
data were reported as median (1st and 3rd quartile); the
categorical data were reported as absolute frequencies
and as percentage frequencies of measured subjects.
The data were entered in an Access XP database and
analysed with Statistica 6.0 (StatSoft, Inc).
Findings
A total of 56/67 patients fulfilling the EULAR/PRINTO/
PRES childhood GPA/WG classification criteria were iden-
tified; the remaining 11 patients were excluded for the fol-
lowing reasons: 1 age at onset > 18 years, 1 for the presence
of other co-morbid condition, 7 excluded by consensus
evaluation, 4 not fulfilling the EULAR/PRINTO/PRES as
previously described [16,17]. Eighty-two% were Caucasians
and 68% females, with median age at the time of disease
onset of 11.7 years (1st and 3rd quartile 8.5-14.5 years) and
with median delay in diagnosis of 4.2 (1.0-9.6) months.
The Table 1 shows in the first column the frequencies of
symptoms before/at the time of diagnosis. The most fre-
quent organ systems involved before/at the time of diagnosis
were ears/nose/throat (ENT) (91%), followed by constitu-
tional (malaise, fever, weight loss) (89%), respiratory (79%),
mucosa and skin (64%), musculoskeletal (59%), and eye
(35%). As indicated in the second column, most of the signs/
symptoms present at the time of diagnosis improved when
evaluated at least 3 months after diagnosis with the excep-
tion of some related to ENT (nasal septum perforation/sad-
dle nose/auricular chondritis, subglottic stenosis/hoarseness/
stridor), pulmonary (wheeze or expiratory dyspnoea, pul-
monary nodules or cavities), and eye (conjunctivitis, keratitis,
blepharitis) involvement which remained substantially un-
changed (data not shown).
When evaluated for ANCA positivity, at the time of
diagnosis, 67% children were ELISA PR3 and 26% ELISA
MPO ANCA positive which decreased to 39% and 19.5%
respectively at the subsequent measurement at least
3 months later; ANCA immunofluorescence staining was
positive in 82.7% at diagnosis and in 47.6% 3 months there-
after. Haematuria/proteinuria was present in > 50% cases at
the time of diagnosis (with necrotizing pauci-immune glom-
erulonephritis in 23/28 [82.1%] biopsies available) and in
>30% at least 3 months later.
The Table 1 also compares the present series (N = 56)
with the paediatric series by Cabral (N = 65) [6] and with 3
adult case series (N = 55-180) [7,10,11]. The organ
Table 1 Frequency of signs/symptoms (number of patients/%) at the time of diagnosis: comparison with published series
Paediatric cohorts Adult cohorts
Signs/symptoms* Current cohort
2010 (N = 56]
Cabral et al.,
2009 [6] (N = 65]
Koldingsnes,
2000 [10] (N = 55]
Mahr, 2008
[11] (N = 180]
Stone, 2010
[7] (N = 197)
Female 38 (68%) 41 (63%) 21 (38%) 99 (50%)
Constitutional 50 (89%) 120 (61%)
Malaise 45/55 (82%) 58 (89%) 47 (85%)
Fever 35 (62%) 35 (54%)
Weight loss 30/52 (58%) 28 (43%) 12 (7%)
Mucosa and skin 36 (64%) 23 (35%) 17 (31%)
Eye 19 (34%) 24 (37%) 21 (38%)
Red eye: conjunctivitis,
keratitis, blepharitis
14/55 (25%) 6 (9%) 36 (20%)
Ears, nose, throat 51 (91%) 52 (80%) 44 (80%) 115 (58%)
Oral/nasal ulcerations 28 (50%) 6 (9%) 26 (14%)
Nasal discharge or recurrent
epistaxis/crusts/granulomata
41 (73%) 42 (65%) 122 (68%)
Nasal septum perforation/saddle nose/
auricular chondritis
9 (16%)
Chronic or recurrent sinus
nasal inflammation
34 (61%) 39 (60%) 98 (54%)
Chronic or recurrent otitis
media/aural discharge
12/55 (22%) 9 (14%) 7 (4%)
Conductive hearing loss 6/54 (11%) 7 (11%) 52 (29%)
Subglottic stenosis/hoarseness/stridor 11 (20%) 9 (14%) 22 (12%)
Respiratory 44 (79%) 52 (80%) 33 (60%) 104 (53%)
Tracheal/endobronchial stenoses, obstruction 9 (16.1%) 11 (6%) 13 (7%)
Haemoptysis, alveolar haemorrhage 14/55 (25%) 29 (45%) 35 (19%) 50 (25%)
Pleuritis 7 (13%) 15 (23%) 16 (9%) 17 (9%)
Pulmonary nodules or cavities 17 (30%) 26/62 (42%) 67 (37%) 45 (23%)
Fixed lung infiltrates 26/55 (47%) 14/62 (23%)
Musculoskeletal 33 (59%)
Muscle pain/tenderness 33 (59%) 37 (57%) 35 (64%)
Arthritis 16/55 (29%) 13 (20%)
Arthralgia 29 (52%)
Other
Central nervous system 8 (14%) 16 (25%) 7 (13%) 39 (20%)
Gastro-intestinal system 9 (16%) 27 (42%) 3 (5%)
Renal 38 (68%) 49 (75%) 42 (76%) 130 (66%)
Laboratory/biopsy
ELISA MPO-ANCA 13/50 (26%) 15 (23%) 65 (33%)
ELISA PR3-ANCA 34/51 (67%) 44 (68%) 131 (67%)
Haematuria or red blood cells casts (RBC/hpf) 35 (63%) 77 (43%)
Glomerulonephritis by renal biopsy 23/28 (82%) 34 (94%)
Childhood ANCA, Cytoplasmic Anti-Neutrophil Cytoplasmic Antibodies; MPO-ANCA, myeloperoxidase-specific Anti-Neutrophil Cytoplasmic Antibodies; PR3-ANCA,
proteinase 3-specific Anti-Neutrophil Cytoplasmic Antibodies; RBC/hpf, red blood cells per high power field.
Blank cells refers to data not available in the related publication.
*Blank fields refers to not available data.
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able with the other paediatric series with some exceptions;
in our series we observed an higher frequency of conjunc-
tivitis, oral/nasal ulceration, fixed lung infiltrates, but
lower frequency of haemoptysis/alveolar haemorrhage,
and gastrointestinal involvement compared with the study
by Cabral et al. [6].
When compared to adult series, adult patients showed
lower frequencies of constitutional (fever, weight loss), ENT
(oral/nasal ulceration, chronic or recurrent otitis media/
aural discharge), respiratory (tracheal/endobronchial sten-
osis, obstruction, haemoptysis/alveolar haemorrhage), and
renal (haematuria or red blood cells casts) involvement,
and a higher frequency of conductive hearing loss.
Discussion
In this study, we have analysed the clinical features at the
time of diagnosis of a large sample of children with GPA/
WG whose data were retrieved from the PRINTO data-
base and were collected on the occasion of the project that
led to the validation of the EULAR/PRINTO/PRES criteria
for the classification of childhood vasculitis [15-17].
Granulomatosis with polyangiits is very rare in chil-
dren and, although it appears to be the same disease
observed in adults, it is not known if childhood
presentations are characterized by differences in the fre-
quency of some clinical features well described in adults.
Indeed, in other connective tissue diseases, such as sys-
temic lupus erythematosus or juvenile dermatomyositis,
the frequency of several clinical manifestations differed
from those observed in adults [18,19].
We have therefore investigated the clinical and labora-
tory features present at the time of diagnosis in our
series of 56 children and compared them with those of
the only other large series of paediatric patients (N = 65)
reported in the literature as well as with 3 large (N > 50)
reported series of adult patients with GPA/WG.
In agreement with previous studies in children, we have
found a gender disproportion, as 68% of our patients were
females, [6] while in adult populations females are less
often affected ranging from 29 to 50% [7,8,10].
In the present paediatric series, the disease was charac-
terised by high frequency of constitutional symptoms,
upper and lower respiratory tract, mucosa, skin and mus-
culoskeletal involvement. The frequencies of symptoms
typically decreased in the first few months after diagnosis,
presumably due to the effect of treatment although data
on treatment modalities were not collected in the data-
base. Our series confirms the previous observation by
Cabral et al that patients with time to diagnosis longer
than 12 months have a higher frequency of ear, nose and
throat and cutaneous symptoms and less renal symptoms
in comparison with earlier diagnosed patients [6]. This
likely reflects the non-specific nature of ENTand cutaneousfeatures in GPA, that occur commonly in children and
hence may not prompt clinicians to initially consider vascu-
litis as the cause. Out of 26 of our patients who underwent
kidney biopsy, 82% had glomerulonephritis, similar to the
finding by Cabral et al. (94.4% of children with biopsies
available) [6]. In adult patients, the data were similar with
73.5% of all patients found with histological evidence of
glomerulonephritis [20].
Comparing the paediatric and adult cohorts, while organ
involvement, signs and symptoms were similar, there were
differences in their frequencies at disease presentation.
Adults had a lower frequency of constitutional, ENT and
respiratory involvement; while hearing loss was more fre-
quent in the adult population.
The current work is limited by the lack of information
on treatment and disease outcomes. In addition, compari-
son of clinical and laboratory findings with literature data
might be hampered by the lack of standardised definition
and by differences in the time of evaluation in the different
series. Moreover our study was likely hampered by incon-
sistencies in laboratory techniques (in particular in rela-
tion to ANCA testing), and by the exclusion of cases in
this series who did not fulfil the new paediatric classifica-
tion criteria for c-GPA. Indeed, we recognise that patients
may present with limited forms of the disease, without ini-
tially fulfilling all criteria for classification and clinicians
must remain vigilant in relation to this presentation in
children.
In conclusion, paediatric patients compared to adults with
GPA/WG have a similar pattern of clinical manifestations
but present different frequencies of organ involvement.
Key messages
Children with GPA/WG are predominantly females/
Caucasians with a median onset age of 11.7 years.
Adult showed lower frequencies of female, constitutional,
ears/nose/throat, respiratory, laboratory involvement and
higher frequency of hearing loss.
Paediatric patients compared to adults have similar
clinical manifestations but different frequencies of organ
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